We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Fevertree Drinks Plc | FEVR | London | Ordinary Share |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
691.00 | 660.00 | 691.00 | 671.50 | 674.00 |
Industry Sector |
---|
BEVERAGES |
Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
---|---|---|---|---|---|---|
12/09/2024 | Interim | GBP | 0.0585 | 26/09/2024 | 27/09/2024 | 18/10/2024 |
26/03/2024 | Final | GBP | 0.109 | 16/05/2024 | 17/05/2024 | 21/06/2024 |
12/09/2023 | Interim | GBP | 0.0574 | 28/09/2023 | 29/09/2023 | 20/10/2023 |
22/03/2023 | Final | GBP | 0.1068 | 20/04/2023 | 21/04/2023 | 02/06/2023 |
13/09/2022 | Interim | GBP | 0.0563 | 29/09/2022 | 30/09/2022 | 21/10/2022 |
16/03/2022 | Final | GBP | 0.1047 | 07/04/2022 | 08/04/2022 | 27/05/2022 |
16/03/2022 | Special | GBP | 0.429 | 07/04/2022 | 08/04/2022 | 27/05/2022 |
15/09/2021 | Interim | GBP | 0.0552 | 30/09/2021 | 01/10/2021 | 22/10/2021 |
18/03/2021 | Final | GBP | 0.1027 | 08/04/2021 | 09/04/2021 | 28/05/2021 |
08/09/2020 | Interim | GBP | 0.0541 | 24/09/2020 | 25/09/2020 | 16/10/2020 |
22/04/2020 | Final | GBP | 0.0988 | 14/05/2020 | 15/05/2020 | 12/06/2020 |
Top Posts |
---|
Posted at 04/12/2024 13:55 by wetdream Nick Train ‘in pain’ over Diageo bet and fund performancePresumably FEVR contributing to his ‘pain’. |
Posted at 02/12/2024 09:14 by castleford tiger ValueHurtsNot in the first half results they were flat. last full year sales were up 20m to 364m which........ is LESS THAN HALF MARKET CAP net profit fell £10m giving a p/e of 50+ I do understand that FEVR has never looked a sensible valuation. The big concern is the UK sales are falling. Tiger |
Posted at 13/9/2024 08:19 by masurenguy Fever-Tree commits to London listing as shares hit 8 year lowA dismal start to the British summer takes shine off sales at the mixers group Announcing first-half results, the company lowered expectations for annual revenue growth to 4-5%, from a previously guided 10% in March. Fever-Tree also cut its 2023 annual forecast at the same stage last year by 15% and took a £3.3m hit on its US division from a production issue. The update sent shares in Fever-Tree down by 100p, or 11.6%, to an eight-year low at 762½p on the Aim index. The stock remains well below the highs of almost £40 achieved before the pandemic and cost-of-living crisis shuttered pubs and wallets. In the first half, Fever-Tree reported a 2% increase in revenue to £170.6m, with the UK down 6% to £50.9 million and Europe down 12% to £44.5m. The US was up 7 per cent to £60.3m, and revenues for the rest of the world were 57% higher at £14.9m. Underlying earnings in the first half jumped by 79% to £18.2m, and the company declared a dividend up 2% at 5.85p per share. Warrillow, 49, who remains chief executive, said that the situation had improved strongly “as summer belatedly arrived. Whilst the first half was challenging, we are controlling the controllables. We’re optimistic of an acceleration of growth across the second half of the year and have seen a much more positive trading performance in July and August.” “Fevertree is doing the right things, gaining share and delivering on gross margin recovery, in a difficult market,” Investec analyst Matthew Webb said. Complete article: No position but onto my watchlist. |
Posted at 13/9/2024 06:25 by laurence llewelyn binliner An interesting watch, I am looking to replace BVIC now bought out by Carlsberg, could FEVR become the next target for a bigger player and more MnA..? 10% off yesterday and could continue south with the revised outlook..? |
Posted at 12/9/2024 07:50 by eezymunny Look at all the competition now:It used to be schweppes massive dominance which was crushed by FEVR. All down hill from here in the UK possibly.... |
Posted at 20/8/2024 09:15 by philanderer Fever-Tree can fizz again, says Deutsche BankPremium mixer business Fever-Tree (FEVR) is trading at an ‘attractive valuation’ despite the challenging backdrop, says Deutsche Bank. Analyst Deirdre Mullaney retained her ‘buy’ recommendation but reduced the target price from £16 to £14.50 on the stock, which rose 2% to 913p on Monday after a full-year preview. The shares have tumbled 9% year-to-date. Despite the downbeat sentiment towards the business, Mullaney said that she ‘continues to believe Fever-Tree is well positioned to capitalise on the long-term premium mixer opportunity given its strong brand equity and large white space opportunity overseas’. Falling costs, new supply agreements and supply chain improvements will allow ‘strong margin recovery than consensus expects in outer years’. However, Mullaney said that near-term the ‘stock will struggle given the challenging market backdrop’, leading her to revise down full-year 2024 and 2025 expectations that reflect a ‘negative weather impact over the summer and weak global spirits market’. The shares trade on 23.1 times price to earnings for 2025 which Mullaney said ‘is an attractive valuation given the long-term growth potential’. Citywire.com |
Posted at 25/7/2024 08:31 by bulltradept US recession looming, FEVR might have a few issues going forward.. |
Posted at 10/6/2024 23:42 by growthpotential Need to see some growth in ROW including Australia. Got the in laws coming over next weekend and have just got some ginger ales, raspberry lemonade and Italian blood orange soda in from the Fever-Tree range. Also spoke to someone else at the supermarket till and she says the FEVR drinks are great |
Posted at 30/5/2024 08:14 by apad I first bought FEVR in 2014 and have increased every year in the 10 years since. Trimmed a few times and my net cost is about half the current price. Divis ignored.My current focus is entirely on the US where they employed americans to manage the company, rather than running it from the UK. As a result they are rolling out steadily and sensibly through States as if they are different countries, creating appropriate mixers and linking with spirits companies. They are doing better at surviving the difficult markets in consumer products than a lot of companies with different products and the brand is difficult to attack. Brands have marketing value that is not represented in the balance sheet but shouldn't be ignored. It's my second biggest holding so I won't be increasing, but I think now is a good entry opportunity. Negative broker comments and a difficult world is the right time to buy solid companies with a lead over the opposition. Especially when they are moving through a country much richer than the ROW. apad |
Posted at 27/1/2024 21:08 by apad In these times of highly fluctuating costs, how many years of revenue buys the company is a good metric.FEVR is about 3.5 years. Given the potential for growth this is not so expensive. Amusingly Bioventix is 19 years 😊 apad |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions